Abigail E. Powell

Abigail E. Powell

Auto-generated profile, based on publicly available information

Abigail E. Powell

Vir Biotechnology, San Francisco, CA 94158, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2022 in Science
Verified
Journal Article
Open access
MMMatthew McCallum
Matthew McCallum
NCNadine Czudnochowski
Nadine Czudnochowski
LRLaura E. Rosen
Laura E. Rosen
SZSamantha K. Zepeda
Samantha K. Zepeda
JBJohn E. Bowen
John E. Bowen
DVDavid Veesler
David Veesler
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern evades antibody-mediated immunity that comes from vaccination or infection with earlier variants due to accumulation of numerous spike mutations. To understand the Omicron antigenic shift, we determined cryo–electron microscopy and x-ray crystal structures of the spike protein and the receptor-binding domain bound to the broadly neutralizing sarbecovirus monoclonal antibody (mAb) S309 (the parent mAb of sotrovimab) and to the human ACE2 receptor. We provide a blueprint for understanding the marked reduction of binding of other therapeutic mAbs that leads to dampened neutralizing activity. Remodeling of interactions between the Omicron receptor-binding domain and human ACE2 likely explains the enhanced affinity for the host receptor relative to the ancestral virus.

18 December 2020 in Science Immunology
Verified
Journal Article
Open access
KRKatharina Röltgen
Katharina Röltgen
APAbigail E. Powell
Abigail E. Powell
OWOliver F Wirz
Oliver F Wirz
BSBryan A. Stevens
Bryan A. Stevens
CHCatherine A. Hogan
Catherine A. Hogan
SBScott Boyd
Scott Boyd
Illness severity in COVID-19 correlates with specificity of serological responses, but antibody levels decrease in most patients.

19 August 2022 in Science
Verified
Journal Article
Open access
JBJohn E. Bowen
John E. Bowen
AAAmin Addetia
Amin Addetia
HDHA DANG
HA DANG
CSCameron Stewart
Cameron Stewart
JBJack T. Brown
Jack T. Brown
DVDavid Veesler
David Veesler
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the previously dominant BA.1 and with BA.4 and BA.5 increasing in prevalence worldwide. We show that the large number of Omicron sublineage spike mutations leads to enhanced angiotensin-converting enzyme 2 (ACE2) binding, reduced fusogenicity, and severe dampening of plasma neutralizing activity elicited by infection or seven clinical vaccines relative to the ancestral virus. Administration of a homologous or heterologous booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 across all vaccines evaluated. Our data suggest that although Omicron sublineages evade polyclonal neutralizing antibody responses elicited by primary vaccine series, vaccine boosters may provide sufficient protection against Omicron-induced severe disease.

5 January 2021 in ACS Central Science
Verified
Journal Article
Closed access
APAbigail E. Powell
Abigail E. Powell
KZKaiming Zhang
Kaiming Zhang
MSMrinmoy Sanyal
Mrinmoy Sanyal
STShaogeng Tang
Shaogeng Tang
PWPayton A. Weidenbacher
Payton A. Weidenbacher
PKPeter S. Kim
Peter S. Kim

18 June 2021 in ACS Central Science
Verified
Journal Article
Open access
OHOle A. W. Haabeth
Ole A. W. Haabeth
JLJulian J. K. Lohmeyer
Julian J. K. Lohmeyer
ASAdrienne Sallets
Adrienne Sallets
TBTimothy R. Blake
Timothy R. Blake
ISIdit Sagiv-Barfi
Idit Sagiv-Barfi
RLRonald Levy
Ronald Levy
The SARS-CoV-2 pandemic has necessitated the rapid development of prophylactic vaccines. Two mRNA vaccines have been approved for emergency use by the FDA and have demonstrated extraordinary effectiveness. The success of these mRNA vaccines establishes the speed of development and therapeutic potential of mRNA. These authorized vaccines encode full-length versions of the SARS-CoV-2 spike protein. They are formulated with lipid nanoparticle (LNP) delivery vehicles that have inherent immunostimulatory properties. Different vaccination strategies and alternative mRNA delivery vehicles would be desirable to ensure flexibility of future generations of SARS-CoV-2 vaccines and the development of mRNA vaccines in general. Here, we report on the development of an alternative mRNA vaccine approach using a delivery vehicle called charge-altering releasable transporters (CARTs). Using these inherently nonimmunogenic vehicles, we can tailor the vaccine immunogenicity by inclusion of coformulated adjuvants such as oligodeoxynucleotides with CpG motifs (CpG-ODN). Mice vaccinated with the mRNA-CART vaccine developed therapeutically relevant levels of receptor binding domain (RBD)-specific neutralizing antibodies in both the circulation and in the lung bronchial fluids. In addition, vaccination elicited strong and long-lasting RBD-specific TH1 T cell responses including CD4+ and CD8+ T cell memory.

12 January 2024 in ACS Nano
Verified
Journal Article
Open access
BOBen S. Ou
Ben S. Ou
JBJulie Baillet
Julie Baillet
VPVittoria C. T. M. Picece
Vittoria C. T. M. Picece
EGEmily C. Gale
Emily C. Gale
APAbigail E. Powell
Abigail E. Powell
EAEric A. Appel
Eric A. Appel
Development of effective vaccines for infectious diseases has been one of the most successful global health interventions in history. Though, while ideal subunit vaccines strongly rely on antigen and adjuvant(s) selection, the mode and time scale of exposure to the immune system has often been overlooked. Unfortunately, poor control over the delivery of many adjuvants, which play a key role in enhancing the quality and potency of immune responses, can limit their efficacy and cause off-target toxicities. There is a critical need for improved adjuvant delivery technologies to enhance their efficacy and boost vaccine performance. Nanoparticles have been shown to be ideal carriers for improving antigen delivery due to their shape and size, which mimic viral structures but have been generally less explored for adjuvant delivery. Here, we describe the design of self-assembled poly(ethylene glycol)-b-poly(lactic acid) nanoparticles decorated with CpG, a potent TLR9 agonist, to increase adjuvanticity in COVID-19 vaccines. By controlling the surface density of CpG, we show that intermediate valency is a key factor for TLR9 activation of immune cells. When delivered with the SARS-CoV-2 spike protein, CpG nanoparticle (CpG-NP) adjuvant greatly improves the magnitude and duration of antibody responses when compared to soluble CpG, and results in overall greater breadth of immunity against variants of concern. Moreover, encapsulation of CpG-NP into injectable polymeric-nanoparticle (PNP) hydrogels enhances the spatiotemporal control over codelivery of CpG-NP adjuvant and spike protein antigen such that a single immunization of hydrogel-based vaccines generates humoral responses comparable to those of a typical prime-boost regimen of soluble vaccines. These delivery technologies can potentially reduce the costs and burden of clinical vaccination, both of which are key elements in fighting a pandemic.